📰 Dose Escalation Study News
Page 3 - Dose Escalation Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Escalation Study. Real-time updates on events, politics, business and more.
November 3, 2022
– Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key...
November 3, 2022
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation...
September 4, 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable...
May 18, 2022
Data demonstrates potential for less frequent drug administrationTTI-0102 was well tolerated with no Serious Adverse Events reportedSupports EU and US regulatory submissions for human efficacy trials
May 16, 2022
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy ... | May 16, 2022
May 12, 2022
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
January 20, 2022
/PRNewswire/ -- ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative...
January 20, 2022
CHARLOTTESVILLE, Va., Jan. 20, 2022 /PRNewswire/ -- ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer an...
January 20, 2022
/PRNewswire/ -- ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative...
December 6, 2021
Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma...